Mechanisms of resistance to topoisomerase I-targeting drugs

DNA topoisomerases are a class of enzymes that alter the topology of DNA and are targets of several anticancer drugs. Camptothecins (CPTs) are a relatively new family of compounds that

specifically target topoisomerase I (Top1). These compounds ‘poison’ Top1 by binding to the Top1–DNA complex in a manner that prevents the religation of DNA. Topotecan and irinotecan are two

CPTs that are approved for the treatment of a variety of malignancies, including colorectal, ovarian, and small cell lung cancers, as well as myeloid malignancies. Although CPTs have proven

to be effective anticancer drugs, resistance is still a critical clinical problem. The mechanisms underlying de novo and acquired clinical resistance to CPTs and the newer classes of Top1

poisons are unclear. However, based on preclinical studies, it is likely that clinical resistance to these drugs is the result of: (1) inadequate accumulation of drug in the tumor, (2)

resistance-conferring alterations in Top1, or (3) alterations in the cellular response to the Top1–CPT interaction. This review will focus on the current knowledge regarding mechanisms of

resistance to CPTs and other Top1-targeting drugs.

We thank Drs Leroy F Liu, Daniel Pilch, and Ahamed Saleem for helpful discussions in writing this review.

Department of Molecular and Cellular Pharmacology, The Cancer Institute of New Jersey, UMDNJ-Robert Wood Johnson Medical School, 195 Little Albany Street, New Brunswick, 08901, NJ, USA

Anyone you share the following link with will be able to read this content: